Figure 1 from Efficacy and safety of Dapagliflozin vs. Canagliflozin in addition to metformin for treatment of type 2 diabetes, a randomized, double-blind, non-inferiority clinical trial | Semantic Scholar
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials - The Lancet Diabetes & Endocrinology
Outcomes in clinical trials compared with real-world data in patients... | Download Table
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - The Lancet Diabetes & Endocrinology
DAPA ACT HF-TIMI 68 – TIMI STUDY GROUP
Dapagliflozin in Real World - ppt download
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists - ScienceDirect
SGLT2 inhibitors – looking beyond glucose-lowering in diabetes | Cochrane UK
New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin | tctmd.com
View of Dapagliflozin: Clinical practice compared with pre-registration trial data | British Journal of Diabetes
Efficacy results of randomized clinical trials with dapagliflozin... | Download Table
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? | SpringerLink
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Diabetes & Endocrinology
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function - Kidney International
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions - ScienceDirect
Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes - Clinical Trials Arena
Safety data summary from the main phase 3 clinical trials of... | Download Table
Ongoing Clinical Trials Assessing Dapagliflozin in Patients with Heart... | Download Scientific Diagram
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
Safety of dapagliflozin in clinical trials for type 2 diabetes mellitus - Virtual Meeting | EASD
Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis | American Society of Nephrology
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials - The Lancet Diabetes & Endocrinology
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM
Selected Clinical Trials of SGLT2 inhibitors in CVD ... | GrepMed
Off the Beaten Path: Non-Insulin Medications to Manage Type 1 Diabetes - ppt download
